reports
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences: HCW Annual Inflammation & Immunology Virtual ConferenceFireside ChatJune 30, 2025, at 11:00 am ET BTIG Virtual Biotechnology Conference 20251x1sJuly 29-30, 2025 Live webcasts and replays, when available, can be found under "News / Events" in the Investors secti...
Mosaicx Launches AI-Native CX Platform and Wins Top Honor at CCW Las V...
Mosaicx Launches AI-Native CX Platform and Wins Top Honor at CCW Las Vegas 2025 Recognized for innovation and inclusion, Mosaicx debuts next-generation Engage platform and earns Best Workplace for Gender Equity Award OMAHA, Neb., June 18, 2025 (GLOBE NEWSWIRE) -- , a leader in AI-powered customer experience solutions and part of WestCX under the West Technology Group portfolio, made a major impact at this year’s Customer Contact Week (CCW) in Las Vegas. The company unveiled a significant update to its flagship intelligent virtual agent platform, Engage, and was honored as CCWomen’s Best...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board o...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. “We are pleased to welcome Dr. Jain to Avalo’s Board of Directors,” said Michael Heffernan, Chairman of the Board. “Rita’s extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biophar...
Mosaicx Unveils AI-Native CX Platform at CCW Las Vegas
Mosaicx Unveils AI-Native CX Platform at CCW Las Vegas CCW Award finalist and pioneer in native AI to lead three speaking sessions OMAHA, Neb., June 05, 2025 (GLOBE NEWSWIRE) -- , a pioneer in customer experience, today announced the launch of the next era of its product. The company will demo the next-generation AI-native platform at (CCW) in Las Vegas from June 9-12. Building on 30 years of CX experience, Mosaicx, part of WestCX, within the West Technology Group portfolio, brings to market a transformational leap in customer engagement, delivering intelligent, adaptive, and seamless...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare Conference 2025, New YorkFireside ChatJune 4, 2025, at 7:35 am ET Oppenheimer Innovators in I&I Summit, New YorkPanelist: “Dermatology: AA, HS, PSO”June 25, 2025, at 10am ET Live webcasts and replays, when a...
Snap Inc: 3 directors
Three Directors at Snap Inc sold after exercising options/sold 243,139 shares at between 8.542USD and 8.595USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compa...
- Dan Salmon
Avalo Reports First Quarter 2025 Financial Results and Recent Business...
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028 WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and...
Apollo Global Management Inc: 1 director
A director at Apollo Global Management Inc sold/gave away 4,230 shares at 0.000USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
West Completes Sale of Notified to Equiniti
West Completes Sale of Notified to Equiniti ISLANDIA, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- West Technology Group, LLC (the “Company” or “West”) has completed the sale of its Notified business to Equiniti (EQ)1, a global leader in shareholder services and advisory firm. “We are pleased to complete the sale of Notified and believe that the complementary strengths of EQ and Notified will elevate the platform to new heights,” said John Shlonsky, President and Chief Executive Officer of West. “Notified has transformed the way businesses connect with stakeholders, and we are confident that u...
- Dan Salmon
US Internet: What we know (and don’t know) about China/de minimis adve...
On Monday, we analyzed GOOGL and META’s potential exposure to China-based advertisers HERE, and discussed META’s exposure more HERE. Last night, SNAP cited weakness from advertisers impacted by changes to the de mimimus exemption as one example of the macro uncertainty that led it to pull 2Q25 guidance (see HERE for full takeaways). Led by Temu and Shein, there is likely high overlap between China-based retailers and those impacted by de minimis exemption changes.
Avalo Therapeutics to Participate in The Citizens Life Sciences Confer...
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at . The...
Sam Meckey Named President of WestCX
Sam Meckey Named President of WestCX ISLANDIA, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- West Technology Group, LLC (the “Company” or “West”), a global leader in technology-enabled services, today announced the appointment of Sam Meckey as President of its WestCX business unit, effective immediately. Mr. Meckey most recently served as the Chief Executive Officer of UpHealth, a publicly traded digital health solutions business. Mr. Meckey joined UpHealth from EXL Services, where he led the healthcare business, driving a transformation of this business from a BPO to a tech-enabled services ...
- Dan Salmon
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Board of Directors during...
Avalo Reports 2024 Financial Results and Recent Business Updates
Avalo Reports 2024 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial ...
West to Divest Notified
West to Divest Notified ISLANDIA, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- West Technology Group, LLC (the “Company” or “West”), a global leader in technology-enabled services, today announced it has entered into a definitive agreement to sell its business to Equiniti (EQ)1, a global leader in shareholder services and advisory firm, for $534.5 million, inclusive of an $80 million earnout. Notified is a leading global technology and services partner to corporate storytellers, including investor relations (“IR”), public relations (“PR”), and corporate communications professionals. Notif...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Health Care Conference, BostonCorporate PresentationMarch 3, 2025, at 3:10 pm ET Leerink Partners Global Healthcare Conference, Miami 1x1 and small group meetings March 12, 2025 Live webcasts and replays, when av...
- Dan Salmon
Snap Inc. (SNAP, Buy, $16 target) 4Q24 Model Update (Buy, target lower...
Our target declines to $16 from $17 owing to lower estimates, partially offset by a higher valuation owing to growing long-term revenue potential after SNAP’s advertiser base doubled in 2024, while Snapchat+ continues to layer in a more predictable subscription revenue stream.
- Dan Salmon
Snap Inc. (SNAP, Buy, $17 target) Two Very Important Things Doubled in...
What's New: In this first take following tonight's results, we focus on: 1. Upside potential grows as advertiser count and Snapchat+ subs both double in 2024 2. DR/Brand trends right in-line with expectations, helped a little by TikTok, and new ad load 3. Very careful rollout of simplified Snapchat progressing, likely takes all of 2025 to complete
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.